A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ASPEN
- 11 May 2016 Time frame for primary endpoint has been changed from 6,12,24 months to 24 months.
- 12 Jan 2016 Results published in the Lancet Oncology
- 03 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.